Edwards Lifesciences (NYSE:EW) Shares Unloaded Rep. Josh Gottheimer

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Edwards Lifesciences Corporation NYSE: EW. In a filing disclosed on December 29th, the Representative disclosed that they had sold between $1,001 and $15,000 in Edwards Lifesciences stock on November 19th. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.Get Edwards Lifesciences alerts:3 Healthcare Pathbreakers With Long-Term TailwindsRepresentative Josh Gottheimer also recently made the following trade(s): Sold $1,001 - $15,000 in shares of Dassault Systemes OTCMKTS: DASTY on 11/21/2025. Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 11/19/2025. Sold $1,001 - $15,000 in shares of HubSpot NYSE: HUBS on 11/19/2025. Sold $15,001 - $50,000 in shares of Fidelity National Information Services NYSE: FIS on 11/19/2025. Sold $1,001 - $15,000 in shares of KKR & Co. Inc. NYSE: KKR on 11/19/2025. Sold $1,001 - $15,000 in shares of BHP Group NYSE: BHP on 11/19/2025. Purchased $1,001 - $15,000 in shares of CSW Industrials NYSE: CSW on 11/17/2025. Sold $1,001 - $15,000 in shares of 3M NYSE: MMM on 10/20/2025. Purchased $1,001 - $15,000 in shares of NiCE NASDAQ: NICE on 10/17/2025. Purchased $1,001 - $15,000 in shares of NetEase NASDAQ: NTES on 10/17/2025. Edwards Lifesciences Trading Down 0.9%Shares of EW stock opened at $86.17 on Wednesday. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The stock has a 50 day simple moving average of $84.28 and a two-hundred day simple moving average of $79.79. The company has a market cap of $50.01 billion, a P/E ratio of 37.14, a PEG ratio of 3.91 and a beta of 0.97. Can financial, healthcare, energy stocks rise as rates stay high?Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm posted $0.67 EPS. The company's quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year. Wall Street Analyst Weigh InSeveral equities research analysts have weighed in on EW shares. Raymond James Financial raised shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and set a $96.00 price target for the company in a research note on Monday, November 3rd. Oppenheimer downgraded Edwards Lifesciences from an "outperform" rating to a "market perform" rating in a research note on Wednesday, October 8th. Mizuho boosted their target price on Edwards Lifesciences from $90.00 to $100.00 and gave the company an "outperform" rating in a research report on Friday, October 31st. Stifel Nicolaus set a $100.00 price target on Edwards Lifesciences and gave the stock a "buy" rating in a research note on Friday, December 5th. Finally, National Bankshares set a $92.00 price objective on Edwards Lifesciences in a research note on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and a consensus price target of $93.95.Why Analysts Say GE's Healthcare Spinoff Has $20 UpsideRead Our Latest Analysis on Edwards LifesciencesInstitutional Trading of Edwards LifesciencesHedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company's stock valued at $5,472,147,000 after buying an additional 365,581 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Edwards Lifesciences by 4.9% in the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company's stock worth $1,617,959,000 after acquiring an additional 977,933 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock valued at $1,478,425,000 after purchasing an additional 1,423,365 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock valued at $1,085,574,000 after purchasing an additional 2,287,783 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Edwards Lifesciences by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company's stock worth $990,074,000 after purchasing an additional 45,555 shares during the period. Institutional investors own 79.46% of the company's stock. Insiders Place Their BetsIn other news, CFO Scott B. Ullem sold 7,700 shares of the company's stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the transaction, the chief financial officer directly owned 39,898 shares of the company's stock, valued at approximately $3,370,184.06. This represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the company's stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the transaction, the vice president directly owned 38,970 shares of the company's stock, valued at $3,264,127.20. The trade was a 22.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 45,465 shares of company stock valued at $3,804,610 over the last three months. Insiders own 0.34% of the company's stock. About Representative GottheimerJosh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.About Edwards Lifesciences (Get Free Report)Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery. In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.Recommended StoriesFive stocks we like better than Edwards LifesciencesDo not delete, read immediatelyThe Crash Has Already Started (Most Just Don’t See It Yet)ALERT: Drop these 5 stocks before January 2026![No Brainer Gold Play]: “Show me a better investment.”INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Edwards Lifesciences Right Now?Before you consider Edwards Lifesciences, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here